Read about the latest advances in FOP research and key data summaries.


Social impact of COVID-19 pandemic felt among people with FOP

Since the start of the COVID-19 pandemic, individuals with fibrodysplasia ossificans progressiva (FOP) have reported decreased satisfaction with their social activities, declining mental health, and a reduction in dental visits, US research shows.


Researchers identify potential FOP biomarkers

US researchers have identified three plasma-soluble biomarkers that may reflect acute and chronic inflammatory states in people with fibrodysplasia ossificans progressiva (FOP).


Senolytics may have a role to play in FOP treatment

Drugs that selectively induce apoptosis of senescent cells may be effective candidates for the treatment of fibrodysplasia ossificans progressiva (FOP) flare-ups via the inhibition of tissue reprogramming and subsequent prevention of endochondral heterotopic ossification (HO), preclinical study findings indicate.


US FOP prevalence higher than expected

The prevalence of fibrodysplasia ossificans progressiva (FOP) in the US is higher than previously believed, according to research published in the Orphanet Journal of Rare Diseases.


Saracatinib identified as potential FOP treatment

Experimental data suggest that the tyrosine kinase inhibitor saracatinib may be a candidate for the treatment of fibrodysplasia ossificans progressiva (FOP), via its inhibition of activin receptor-like kinase (ALK)2.


FOP great toe shows two developmental phenotypes

A detailed analysis of radiographs from individuals with ACVR1R206H -mutated fibrodysplasia ossificans progressiva (FOP) has found that great toe malformations result from monophalangeal and biphalangeal phenotypes.

Keep up-to-date with FOP eAlerts

Login / register

Forgotten password?

FOP clinical diagnosis quiz image references

Question 1

Question 2

Question 3

Question 4

Question 5

Question 6

Question 7

Question 8

Question 9

Question 10